ArticleJournal of natural medicines2016
Catalpol reduces the production of inflammatory mediators via PPAR-γ activation in human intestinal Caco-2 cells.
Article in Journal of natural medicines, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- Clinical Efficacy of Modified Yanghe Decoction in Ankylosing Spondylitis: A Randomized Controlled Trial.Medical science monitor : international medical journal of experimental and clinical research · 2018Trial
- Transmembrane Protein 43: Molecular and Pathogenetic Implications in Arrhythmogenic Cardiomyopathy and Various Other Diseases.International journal of molecular sciences · 2025Review
- Catalpol protects mouse ATDC5 chondrocytes against interleukin-1β-induced catabolism.Histology and histopathology · 2024Article
- Catalpol inhibits hepatic stellate cell activation by reducing the formation and changing the contents of hepatocyte-derived extracellular vesicles.Journal of cell communication and signaling · 2023Article
- Anti-Inflammatory and Antioxidant Chinese Herbal Medicines: Links between Traditional Characters and the Skin Lipoperoxidation "Western" Model.Antioxidants (Basel, Switzerland) · 2022Review
- Protective effects of catalpol on mitochondria of hepatocytes in cholestatic liver injury.Molecular medicine reports · 2020Article
- Effects of catalpol on asthma by airway remodeling via inhibiting TGF-β1 and EGF in ovalbumin-induced asthmatic mice.American journal of translational research · 2020Article
- TMEM43-S358L mutation enhances NF-κB-TGFβ signal cascade in arrhythmogenic right ventricular dysplasia/cardiomyopathy.Protein & cell · 2019Article
- Inhibitory effects of catalpol coordinated with budesonide and their relationship with cytokines and Interleukin-13 expression.American journal of translational research · 2019Article
- Exploring the Mechanism of Dangguiliuhuang Decoction Against Hepatic Fibrosis by Network Pharmacology and Experimental Validation.Frontiers in pharmacology · 2018Article
- Mangiferin Inhibits IL-1β-Induced Inflammatory Response by Activating PPAR-γ in Human Osteoarthritis Chondrocytes.Inflammation · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Catalpol, a major iridoid glycoside present in Rehmannia glutinosa, has been reported to show a variety of pharmacological properties. However, the molecular mechanism underlying the anti-inflammatory effect of catalpol in intestinal cells remains poorly understood. The present study was aimed at investigating the effects of catalpol on the production of inflammatory mediators and its underlying signaling pathways in human intestinal Caco-2 cells. Catalpol significantly inhibited IL-1β-induced mRNA synthesis and protein production of pro-inflammatory cytokines, including IL-6, IL-8, and MCP-1. Further investigation of the molecular mechanism revealed that the anti-inflammatory effect of catalpol in Caco-2 cells is similar to that of troglitazone-a synthetic peroxisome proliferator-activated receptor (PPAR)-γ agonist-on intestinal inflammation mediated by PPAR-γ activation. These findings suggest that the clinical application of medicinal plants that contain catalpol may lead to a partial prevention of intestinal inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.